<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        107-172-97
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1997
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NAPROX D.S 500MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NAPROXEN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        14.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Pharmaceuticals PLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Pharmaceuticals PLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Hikma Pharmaceuticals PLC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AE02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Naprox belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs), which are used to reduce inflammation and pain in joints and muscles.</p><p>Naprox tablets are used to treat:</p><ul><li>Diseases of joints such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis. Naprox cannot cure arthritis but is used to give relief of some symptoms such as inflammation, swelling, stiffness and joint pain.</li><li>Attacks of gout.</li><li>Muscle and bone disorders such as cervical spondylitis, low back pain, strains and sprains, muscular pain and stiffness (fibrositis) and inflammation of tendons (tenosynovitis).</li><li>It is also used to treat painful menstrual periods.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Naprox if you are allergic (hypersensitive) to: </strong></p><ul><li>Naproxen, naproxen sodium or any of the other ingredients of Naprox (see listed in section 6).</li><li>Aspirin, other NSAIDs or any other pain relief medicines (such as ibuprofen or diclofenac).</li></ul><p><strong>Do not take Naprox if: </strong></p><ul><li>You have now or have ever had any problems with your stomach or gut (intestine) like an ulcer or bleeding.</li><li>You have previously experienced bleeding or perforation in your stomach while taking NSAIDs.</li><li>You have severe problems with your kidneys, liver or heart.</li><li>You are in the last three months of pregnancy.</li></ul><p>Do not take Naprox if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking Naprox.</p><p><strong>Warnings and precautions</strong></p><p>If you have heart problems, previous stroke or think that you might be at risk of these conditions (for example if you have high blood pressure, diabetes or high cholesterol or are a smoker) you should discuss your treatment with your doctor or pharmacist.</p><p><em>&nbsp;</em>Talk to your doctor or pharmacist before taking Naprox if any of the following apply to you:</p><ul><li>Asthma or allergies (like hay fever)= or have had swelling of the face, lips, eyes or tongue in the past.</li><li>A feeling of weakness (perhaps because of an illness) or you are an older person.&nbsp;</li><li>Lumps in your nose (polyps) or you sneeze a lot or have a runny, blocked, or itchy nose (rhinitis).</li><li>Problems with your kidneys or liver.</li><li>Problems with the way that your blood clots.</li><li>Problems with the blood vessels (arteries) anywhere in your body.</li><li>Too much fat (lipid) in your blood (hyperlipidaemia).</li><li>An autoimmune condition, such as &lsquo;systemic lupus erythematosus&rsquo; (SLE, causes joint pain, skin rashes and fever) and colitis or Crohn&rsquo;s disease (conditions causing inflammation of the bowel, bowel pain, diarrhoea, vomiting and weight loss).</li></ul><p>If any of the above apply to you, or if you are not sure, talk to your doctor or pharmacist before you take Naprox.</p><p><strong>&nbsp;Other medicines and Naprox</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines that you buy without a prescription and herbal medicines. In particular, tell your doctor or pharmacist if you are taking:</p><ul><li>Other pain killers, like aspirin, ibuprofen, diclofenac and paracetamol.</li><li>Medicine to stop your blood clotting, like warfarin, heparin or clopidogrel.&nbsp;</li><li>A hydantoin (for epilepsy), like phenytoin.</li><li>Sulfonamide medicines, like hydrochlorothiazide, acetazolamide, indapamide and including sulfonamide antibiotics (for infections).</li><li>A sulfonylurea (for diabetes), like glimepiride or glipizide.</li><li>An &lsquo;ACE inhibitor&rsquo; or any other medicine for high blood pressure like cilazapril, enalapril or propranolol.</li><li>An angiotensin-II receptor antagonist, like candesartan, eprosartan or losartan.</li><li>A diuretic (water tablet) (for high blood pressure), like furosemide.</li><li>A &lsquo;cardiac glycoside&rsquo; (for heart problems), like digoxin.</li><li>A steroid (for swelling and inflammation), like hydrocortisone, prednisolone and dexamethasone.</li><li>A &lsquo;quinolone antibiotic&rsquo; (for infections), like ciprofloxacin or moxifloxacin.</li><li>Certain medicines for mental health problems like lithium or &lsquo;SSRIs&rsquo; like fluoxetine or citalopram.</li><li>Probenecid (for gout).</li><li>Methotrexate (used to treat skin problems, arthritis or cancer).</li><li>Ciclosporin or tacrolimus (for skin problems or after an organ transplant).</li><li>Zidovudine (used to treat AIDS and HIV infections).</li><li>Mifepristone (used to end pregnancy or to bring on labour if the baby has died).</li><li>Aspirin/ acetylsalicylic acid to prevent blood clots.</li></ul><p>If any of the above apply to you, or if you are not sure, talk to your doctor or pharmacist before you take Naprox.</p><p><strong>Naprox with Food and Drink</strong></p><p>Naprox Should be taken preferably with or after food.</p><p><strong>&nbsp;Pregnancy and breast feeding</strong></p><ul><li>Do not take Naprox if you are in the last three months of pregnancy, as it can harm your baby.</li><li>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</li><li>Naprox may make it more difficult to become pregnant. You should tell your doctor if you are planning to become pregnant or if you have problems becoming pregnant.</li></ul><p><strong>Driving and using machines </strong></p><p>Naprox may make you tired, drowsy, dizzy, have problems with your eyesight and balance, depressed or have difficulty sleeping. Talk to your doctor if any of these happen to you and do not drive or use any tools or machines.</p><p><strong>Naprox contains lactose monohydrate and sodium </strong></p><p>Naprox contains lactose monohydrate. Each 250 mg and 500 mg film-coated tablet contains 100 mg or 200 mg lactose monohydrate; respectively. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p><p>Naprox contains sodium. Each 250 mg and 500 mg film-coated tablet contains 28.441 mg or 56.882 mg sodium (main component of cooking/table salt); respectively. This is equivalent to 1.42% and 2.84% of the recommended maximum daily dietary intake of sodium for an adult. Patients on a sodium controlled diet should take this into consideration.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medicines such as Naprox may be associated (linked) with a small increased risk of heart attack (&lsquo;myocardial infarction&rsquo;) or stroke. Any risk is more likely with higher doses and prolonged (longer term) treatment. Do not exceed (take more than) the recommended dose or duration (length) of treatment.</p><p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>For oral administration (by mouth)</p><p>Swallow the tablets whole with a little water, with or after food.</p><p>While you are taking Naprox tablets your doctor will want to see you to check you are on the right dose for you and look for any side effects. This is particularly important if you are elderly.</p><p>The recommended dose is:</p><p><strong>Adults </strong></p><p><em>Rheumatoid arthritis, osteoarthritis and ankylosing spondylitis</em></p><ul><li>The usual dose is between 500 mg and 1000 mg.</li><li>The dose can be taken all at once, or split in two and taken twice a day.</li></ul><p><em>Gout</em></p><ul><li>The usual starting dose is 750 mg, followed by a 250 mg tablet every 8 hours as needed.</li></ul><p><em>Muscle, joint or tendon problems and period pain </em></p><ul><li>The usual starting dose is 500mg as a single dose then 250mg tablet every 6-8 hours as necessary. Up to a maximum of 1250mg a day may be given after the first day.</li></ul><p><strong>Children (over 5 years)</strong></p><p><em>&nbsp;juvenile rheumatoid arthritis</em></p><ul><li>10mg/kg/day taken in 2 doses at 12-hour intervals.</li><li>Naprox is not recommended for use in any other indication in children under 16 years of age.</li></ul><p><strong>Older people and people with liver and kidney problems </strong></p><ul><li>Your doctor will decide your dose, it will usually be lower than that for other adults.</li></ul><p><strong>If you take more Naprox than you should</strong></p><ul><li>Contact your doctor, pharmacist or nearest hospital casualty department immediately if you have taken more tablets than you should. Take the medicine pack with you.</li></ul><p><strong>Symptoms of overdose</strong><strong> </strong></p><p>Headache, feeling or being sick, heartburn, epigastric pain (upset stomach), diarrhoea, bleeding of the stomach or intestines, disorientation, temporary changes to liver functions, reducing the time it takes for your blood to clot, stopping breathing, body produces too much acid, unconsciousness, drowsiness, dizziness, ringing or buzzing in the ears, fainting, fits and excitation.</p><p><strong>If you forget to take Naprox</strong></p><p>If you forget to take your tablets, take your next dose as soon as you remember, unless it is nearly time for your next dose.</p><p>Do not take a double dose to make up for one you have missed.</p><p><strong>If you stop taking Naprox </strong></p><p>Talk to your doctor before you stop taking the tablets and follow their advice.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines this medicine can cause side effects, although not everybody will get them.</p><p>Medicines such as Naprox may be associated with a small increased risk of heart attack (&lsquo;myocardial infarction&rsquo;) or stroke.</p><p><strong><em>Important side effects to look out for: </em></strong></p><p>Stop taking Naprox and tell a doctor straight away if any of the following side effects happen. You may need urgent medical treatment:</p><p><strong>Serious stomach or gut problems </strong></p><p>Signs include:</p><ul><li>Bleeding from the stomach, seen as vomit which has blood in it, or bits that look like coffee grounds.</li><li>Bleeding from your back passage (anus), seen as passing black sticky bowel motions (stools) or bloody diarrhoea.</li><li>Ulcers or holes forming in your stomach or gut sometimes fatal particularly in elderly. Signs include upset stomach, stomach pain, fever, feeling or being sick.&nbsp;</li><li>Problems with your pancreas. Signs include severe stomach pain which spreads to your back.</li><li>Worsening of ulcerative colitis or Crohn&rsquo;s disease, seen as pain, diarrhoea, vomiting and weight loss.</li></ul><p><strong>Allergic reactions</strong></p><p>Signs include:</p><ul><li>Sudden swelling of your throat, face, hands or feet.</li><li>Difficulty breathing, tightness in your chest.</li><li>Skin rashes, blisters or itching.</li></ul><p><strong>Severe skin rashes</strong></p><p>Signs include:</p><ul><li>A severe rash that develops quickly, with blisters or peeling of your skin and possibly blisters in your mouth, throat or eyes. Fever, headache, cough and aching body may happen at the same time.</li><li>Blistering of skin when exposed to sunlight (porphyria cutanea tarda) seen most on arms, face and hands.</li></ul><p><strong>Liver problems</strong></p><p>Signs include:</p><ul><li>Yellowing of your skin or the whites of your eyes (jaundice).</li><li>Feeling tired, loss of appetite, feeling or being sick and pale coloured stools (hepatitis) and problems (including hepatitis), shown in blood tests.</li></ul><p><strong>Heart attack</strong></p><p>Signs include:</p><ul><li>Chest pain which may spread to your neck and shoulders and down your left arm.</li></ul><p><strong>Stroke</strong></p><p>Signs include:</p><ul><li>Muscle weakness and numbness. This may only be on one side of your body.</li><li>A suddenly altered sense of smell, taste, hearing or vision, confusion.</li></ul><p><strong>&nbsp;Meningitis</strong></p><p>Signs include:</p><ul><li>Fever, feeling or being sick, a stiff neck, headache, depression, vertigo, drowsiness, sensitivity to bright light and confusion (most likely in people with autoimmune conditions such as &lsquo;systemic lupus erythematosus&rsquo;).</li></ul><p>If you notice any of the serious side effects mentioned above, stop taking Naprox and tell your doctor straight away.</p><p><strong><em>Other possible side effects: </em></strong></p><p><strong>Stomach and gut</strong></p><ul><li>Heartburn, indigestion, gastritis (an inflammation of the lining of the stomach), dry mouth, throat irritation, decreased appetite, stomach ache, feeling sick or being sick, constipation, diarrhoea, wind, inflammation of the food pipe (oesophagus).</li></ul><p>Side effects on the gut can be fatal, particularly in the elderly.</p><p><strong>Blood </strong></p><ul><li>A reduction in the number of platelets (thrombocytopenia).</li><li>Decreased platelet aggregation.</li><li>An increase or decrease in white blood cells.</li><li>A reduction of the quantity of the oxygen-carrying pigment haemoglobin in the blood (anaemia) caused by decreased production (aplasia) or increased destruction (haemolysis) of red blood cells.</li><li>High levels of potassium in the blood (hyperkalaemia) or inflammation of blood vessels (vasculitis).</li></ul><p><strong>Mental illness </strong></p><ul><li>Having difficulty sleeping or changes in your patterns of dreaming.</li><li>Depression.</li><li>Confusion or seeing and possibly hearing things that are not there (hallucinations).</li></ul><p><strong>Nervous system </strong></p><ul><li>Headache.</li><li>Fits or seizures, feeling dizzy or light-headed or sleepy.</li><li>Pins and needles or numbness of your hands and feet.</li><li>Difficulty with your memory or concentration.</li></ul><p><strong>Eyes and ears </strong></p><ul><li>Changes to your eyesight, eye pain.</li><li>Changes to your hearing, including ringing in the ears (tinnitus) and hearing loss.</li><li>Dizziness that causes problems with your balance.</li></ul><p><strong>Heart and circulation </strong></p><ul><li>Swelling of your hands, feet or legs (oedema), this may be with chest pains, tiredness, shortness of breath (cardiac failure).</li><li>A fluttering feeling in your heart (palpitations), slow heart beat or high blood pressure.</li><li>Problems with the way your heart pumps blood around the body or damage to your blood vessels. Signs may include tiredness, shortness of breath, feeling faint, general pain.</li></ul><p><strong>Chest </strong></p><ul><li>Difficulty breathing, including shortness of breath, wheezing or coughing.</li><li>Pneumonia or swelling of your lungs.</li></ul><p><strong>Skin and hair </strong></p><ul><li>Skin rashes including redness, hives, pimples and blisters on your body and face.</li><li>Bruising, itching, sweating, skin being more sensitive to the sun or hair loss.</li></ul><p><strong>Urinary </strong></p><ul><li>Blood in your water (urine) or kidney problems.</li></ul><p><strong>Other<u> </u></strong></p><ul><li>Thirst, fever, feeling tired or generally unwell.</li><li>A sore mouth or mouth ulcers.</li><li>Muscle pain or weakness.</li><li>Problems for women in getting pregnant.</li><li>&lsquo;Systemic lupus erythematosus&rsquo; (SLE). Signs include fever, rash, problems with your kidneys and joint pain.</li></ul><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not store above 30&deg;C.</p><p>Store in original package in order to protect from light.</p><p>Do not use this medicine after the expiry date which is stated on the package after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is Naproxen sodium.</p><p>Each film-coated tablet of Naprox 250 mg contains 275 mg naproxen sodium equivalent to 250 mg naproxen.</p><p>Each film-coated tablet of Naprox D.S. 500 mg contains 550 mg Naproxen sodium equivalent to 500 mg Naproxen.</p><p>The other ingredients are: <em>Tablet core:</em> Sodium lauryl sulfate, povidone, lactose monohydrate, croscarmellose sodium, microcrystalline cellulose, hydrogenated vegetable oil, colloidal silicon dioxide and magnesium stearate. <em>Tablet coat:</em> Opadry white.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Naprox 250 mg Film-coated Tablets are white capsule-shaped film-coated tablets, of a medium size and engraved with “H1” in PVC/PVDC-aluminum foil blisters. 

Pack size: 20 Film-coated tablets. 

Naprox D.S. 500 mg Film-coated Tablets are white capsule-shaped film-coated tablets engraved with “H2” in PVC/PVDC-aluminum foil blisters.

Pack size: 10 Film-coated tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Manufacturer </strong></p><p>Hikma Pharmaceuticals</p><p>Bayader Wadi El Seer</p><p>Industrial Area</p><p>P.O. Box 182400</p><p>Amman 11118, Jordan</p><p>Tel: + (962-6) 5802900</p><p>Fax: + (962-6) 5817102</p><p>Website: www.hikma.com</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects, you can also help provide more information on the safety of this medicine.</p><ul><li>&nbsp; &nbsp; Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>&nbsp; &nbsp; Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 03/2021; version number SA2.0.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي نابروكس إلى&nbsp; مجموعة من الأدوية تسمى&nbsp; مضادات التهاب غير ستيرويدي و التي تستخدم لتقليل الالتهاب و ألم المفاصل والعضلات.</p><p dir="RTL">يستخدم نابروكس لعلاج:</p><ul dir="rtl"><li>أمراض المفاصل مثل التهاب المفاصل الروماتيدي، هشاشة العظام و التهاب الفقار المقسط. لا يستطيع نابروكس علاج التهاب المفاصل لكنه يستخدم لتخفيف بعد الأعراض مثل الالتهاب، الانتفاخ، التصلب و ألم المفاصل.</li><li>نوبات النقرص.</li><li>مشاكل العظام و العضلات مثل التهاب الفقار العنقي، ألم أسفل الظهر، الالتواءات و الرضوض، ألم العضلات و التصلبات ( الالتهاب ليفي) و التهاب الأوتار (التهاب غمد الوتر).</li><li>يستخدم أيضا لعلاج آلام الدورة الشهرية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول نابروكس إذا كنت تعاني من حساسية (فرط الحساسية) ﻠِ:</strong></p><ul dir="rtl"><li>نابروكسين، نابروكسين الصوديوم أو لأي من المكونات الأخرى في نابروكس (المذكورة في القسم 6).</li><li>أسبرين، مضادات الالتهاب غير الستيرويدية الأخرى أو أي من أدوية تخفيف الألم الأخرى (مثل إيبوبروفين أو ديكلوفيناك).</li></ul><p><strong>لا تتناول نابروكس إذا: </strong></p><ul dir="rtl"><li>كنت تعاني حاليًا أو في أي وقت مضى من أي مشاكل بالمعدة أو الأمعاء مثل القرح أو النزف.</li><li>تعرضت سابقاً لنزف أو ثقب بالمعدة عند تناول مضادات الالتهاب غير الستيرويدية.</li><li>كنت تعاني من مشاكل شديدة بالكلى، الكبد أو القلب.</li><li>كنتِ في الأشهر الثلاثة الأخيرة من الحمل.</li></ul><p>لا تتناول نابروكس إذا كان أي مما سبق ينطبق عليك. استشر طبيبك أو الصيدلي قبل تناول نابروكس إذا لم تكن متأكدًا.</p><p><strong>الاحتياطات والتحذيرات </strong></p><p dir="RTL">يجب أن تناقش علاجك مع الطبيب أو الصيدلي إذا كنت تعاني من مشاكل بالقلب، سكتة دماغية سابقة أو تعتقد أنك معرض للإصابة بأي من هذه الحالات (على سبيل المثال إذا كنت تعاني من ارتفاع ضغط الدم، السكري أو ارتفاع نسبة الكوليسترول أو إذا كنت مدخناً).</p><p><em>&nbsp;تحدث مع طبيبك، أو الصيدلي قبل استخدام نابروكس إذا انطبق عليك أي مما يلي:</em></p><ul dir="rtl"><li>الربو أو الحساسية (مثل حمى الكلأ) أو تعرضت فيما سبق لتورم بالوجه، الشفتين، العينين أو اللسان.</li><li>شعور بالضعف (ربما بسبب المرض) أو إذا كنت كبيراً بالسن.</li><li>تكتلات بالأنف (سلائل أنفية) أو تعاني من كثرة العطاس أو لديك سيلان، انسداد أو حكة بالأنف (التهاب الأنف).</li><li>مشاكل بالكلى أو الكبد.</li><li>مشاكل في طريقة تخثر الدم.</li><li>مشاكل في الأوعية الدموية (الشرايين) في أي مكان من جسمك.</li><li>ارتفاع نسبة الدهون في الدم (فَرْطُ شَحْميَّاتِ الدَّم).</li><li>حالة تؤثر على المناعة الذاتية مثل &rsquo;الذئبة الحماميَة المجموعيَة&lsquo; (والتي تسبب آلام بالمفاصل، طفح جلدي وحمى) والتهاب القولون أو مرض كرون (حالات تسبب عدوى وألم بالأمعاء، إسهال، قيئ وفقدان للوزن).</li></ul><p>استشر طبيبك أو الصيدلي قبل أن تتناول نابروكس إذا كان أي مما سبق ينطبق عليك أو إذا لم تكن متأكدًا.</p><p><strong>&nbsp;الأدوية الأخرى ونابروكس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً، أو قد تتناول أي أدوية أخرى. يشمل ذلك الأدوية التي تشتريها بدون وصفة طبية والأدوية العشبية. أبلغ طبيبك أو الصيدلي إذا كنت تتناول تحديدًا ما يلي:</p><ul dir="rtl"><li>مسكنات ألم أخرى مثل أسبرين، إيبوبروفين، ديكلوفيناك وباراسيتامول.</li><li>أدوية منع تخثر الدم مثل، وارفارين، هيبارين أو كلوبيدوجريل.</li><li>أدوية من فئة الهيدانتوين (للصرع)، مثل فينيتوين.</li><li>أدوية السلفوناميد، مثل هيدروكلوروثيازيد، أسيتازولاميد، إينداباميد، ويشمل ذلك مضادات السلفوناميد الحيوية (لعلاج العدوى).</li><li>أدوية من فئة السلفونيليوريا (لعلاج السكري) مثل جليميبيريد أو جليبيزيد.</li><li>أحد &quot;مثبطات الإنزيم المحول للأنجيوتنسين&quot; أو أي دواء آخر لعلاج ارتفاع ضغط الدم مثل سيلازابريل، إينالابريل أو بروبرانولول.</li><li>أحد مضادات مستقبلات الانجيوتنسين-2 مثل كانديسارتان، إيبروسارتان أو لوسارتان.</li><li>أحد مدرات البول (قرص الماء) (لعلاج ارتفاع ضغط الدم)، مثل فوروسيميد.</li><li>أحد &rsquo;الغليكوزيدات القلبية&lsquo; (لعلاج مشاكل القلب)، مثل ديجوكسين.</li><li>الستيرويد (لعلاج التورم والالتهاب)، مثل هيدروكورتيزون، بريدنيزولون وديكساميثازون.</li><li>أدوية من فئة &quot;المضادات الحيوية كوينولون&quot; (لعلاج العدوى)، مثل سيبروفلوكساسين أو موكسيفلوكساسين.</li><li>أدوية معينة لعلاج مشاكل الصحة النفسية مثل ليثيوم أو &quot;مثبطات استرداد السيروتونين الانتقائية&quot; مثل فلوكسيتين أو سيتالوبرام.&nbsp; &nbsp;</li><li>بروبينيسيد (للنقرس).</li><li>ميثوتريكسات (لعلاج مشاكل الجلد، التهاب المفاصل أو السرطان).</li><li>سيكلوسبورين أو تاكروليموس (لعلاج مشاكل الجلد أو بعد زراعة الأعضاء).</li><li>زيدوفودين (لعلاج عدوى الإيدز وفيروس نقص المناعة المكتسبة البشري).</li><li>ميفيبريستون (يُستخدم لإنهاء الحمل أو لحث المخاض في حالة وفاة الجنين).</li><li>أدوية منع تخثر الدم مثل، أسبرين/حَمْضُ الأسيتيل ساليسيليك.</li></ul><p dir="RTL">استشر طبيبك أو الصيدلي قبل أن تتناول نابروكس إذا كان أي مما سبق ينطبق عليك أو إذا لم تكن متأكدًا.</p><p><strong>نابروكس مع الطعام و الشراب</strong></p><p>يجب تناول نابروكس بالأفضلية مع أو بعد الطعام</p><p dir="RTL"><strong>&nbsp;الحمل والرضاعة</strong></p><ul dir="rtl"><li>لا تتناولِ نابروكس إذا كنتِ في الأشهر الثلاثة الأخيرة من الحمل، لأنه قد يؤذي الجنين.</li><li>يرجى استشارة طبيبك أو الصيدلي قبل تناول هذا الدواء إذا كنت حاملاً أو مرضع، أو تعتقدين بأنك حاملاً أو تخططين لذلك.</li><li>نابروكس قد يزيد من صعوبة حدوث الحمل. لذا ينبغي أن تخبري طبيبك إذا كنتِ تخططين للحمل أو كانت لديك مشاكل في حدوث حمل.</li></ul><p><strong>القيادة واستخدام الآلات </strong></p><p dir="RTL">قد يسبب لك نابروكس التعب، النعاس، الدوخة، مشاكل بالرؤية والتوازن، الاكتئاب أو صعوبة في النوم. استشر طبيبك إذا تعرضت لأي من ذلك وابتعد عن القيادة واستخدام الأدوات أو الآلات.</p><p dir="RTL"><strong>يحتوي نابروكس على اللاكتوز أحادي الماء والصوديوم</strong></p><p dir="RTL">يحتوي نابروكس على اللاكتوز أحادي الماء. يحتوي كل 250 ملغم و500 ملغم قرص مغطى بطبقة رقيقة على 100 ملغم أو 200 ملغم لاكتوز أحادي الماء؛ على التوالي. إذا أخبرك طبيبك بأن لديك عدم تحمل لبعض السكريات، اتصل بطبيبك قبل تناول هذا المستحضر الدوائي.</p><p dir="RTL">يحتوي نابروكس على الصوديوم. يحتوي كل 250 ملغم و500 ملغم قرص مغطى بطبقة رقيقة على 28,441 ملغم أو 56,882 ملغم صوديوم (المكون الرئيسي لملح الطبخ/الطعام)؛ على التوالي. &nbsp;هذا يعادل 1,42% و2,84% من الحد الأقصى الموصى به من النظام الغذائي اليومي للصوديوم للبالغ. لذا، يجب أن يراعي ذلك المرضى الذين يتبعون نظامًا غذائيًا مضبوط الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يرتبط تناول الأدوية مثل نابروكس بزيادة طفيفة في خطر حدوث نوبة قلبية (&rsquo;احتشاء عضلة القلب&lsquo;) أو سكتة دماغية. ويزداد خطر حدوث ذلك مع الجرعات الأكبر والعلاج المطوّل (طويل الأمد). لا تتجاوز الحد الموصى به للجرعة أو مدة العلاج.</p><p dir="RTL">قم دائماً بتناول دوائك تماماً كما وصفه لك طبيبك أو الصيدلي. تحقق من طبيبك أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">للاستخدام عن طريق الفم</p><p dir="RTL">ابلع الأقراص كاملة مع قليل من الماء، أثناء تناول الطعام أو بعده.</p><p dir="RTL"><strong>&nbsp;</strong>سيرغب طبيبك في رؤيتك أثناء تناولك نابروكس للتأكد من أن الجرعة التي تتناولها صحيحة وللكشف عن أي آثار جانبية. ويعد ذلك مهماً بالأخص إذا كنت مسناً.</p><p dir="RTL">الجرعة الموصى بها هي:</p><p dir="RTL"><strong>البالغون </strong></p><p dir="RTL"><em>التهاب المفاصل و</em><em>التهاب الفقار المُقَسِّط</em></p><ul dir="rtl"><li>تتراوح الجرعة المعتادة بين 500 ملغم و1000 ملغم.</li><li>يمكن تناول الجرعة كاملة مرة واحدة، أو تقسيمها وتناولها على مرتين في اليوم. &nbsp;</li></ul><p dir="RTL"><em>النقرس</em></p><ul dir="rtl"><li>جرعة البدء المعتادة هي 750 ملغم، تُتْبع بـقرص 250 ملغم كل 8 ساعات حسب الحاجة.</li><li>مشاكل في العضلات، المفاصل أو الأوتار وآلام الدورة الشهرية</li><li>جرعة البدء المعتادة هي 500 ملغم، تُتْبع بـقرص 250 ملغم كل 6 إلى 8 ساعات حسب الحاجة.</li></ul><p dir="RTL"><strong>الأطفال الذين تجاوزوا عمر 5 سنوات، </strong><strong>التهاب المفاصل الروماتويدي </strong></p><ul dir="rtl"><li>الجرعة المعتادة هي 10 ملغم/كلغم من وزن الجسم كل يوم.</li><li>تُقسّم وتعطى الجرعة على مرتين يفصل بين كل منهما 12 ساعة.</li></ul><p dir="RTL"><strong>كبار السن ومرضى الكبد والكلى </strong></p><ul dir="rtl"><li>سيحدد لك طبيبك الجرعة، ستكون عادةً أقل مما يتناوله بقية البالغين.</li></ul><p>يجب أن تتأكد من تناولك ما يكفي من السوائل (حافظ على ترطيب الجسم) أثناء تناول نابروكس. ويعد ذلك مهماً بالأخص لدى الأشخاص الذين يعانون من مشاكل في الكلى.</p><p><strong>إذا تناولت نابروكس أكثر من اللازم</strong></p><p dir="RTL">إذا تناولت جرعة زائدة من نابروكس، استشر الطبيب أو الصيدلي أو توجه إلى المستشفى على الفور، وخذ عبوة الدواء معك.</p><p dir="RTL"><strong>أعراض الجرعة الزائدة </strong></p><p>صداع، غثيان أو قيء، حرقة، ألم في المعدة (اضطراب في المعدة)، إسهال، نزيف في المعدة أو الأمعاء،ارتباك، تغير مؤقت في وظائف الكبد، تقليل الوقت اللازم لحدوث تخثر في الدم، توقف التنفس، إنتاج الجسم كميات كبيرة من الحمض، فقدان الوعي،الشعور بالنعاس، دوخة، رنين أو طنين الأذن، الإغماء، النوبات و الإثارة.</p><p><strong>إذا نسيت تناول نابروكس</strong></p><p dir="RTL">إذا نسيت تناول جرعة، تناول الجرعة التالية فورا عند التذكر إلا إذا كان موعد الجرعة التالية قد اقترب.</p><p>لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول نابروكس</strong></p><p>أخبر طبيبك قبل التوقف عن تناول الأقراص و اتبع نصيحته.</p><p>إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، اسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبية، إلا أنه ليس بالضرورة أن تحدث لدى جميع مستخدمي هذا الدواء.</p><p>قد يرتبط تناول الأدوية مثل نابروكس بزيادة طفيفة في خطر حدوث نوبة قلبية (&rsquo;احتشاء عضل القلب&lsquo;) أو سكتة دماغية.</p><p><em>&nbsp;</em><strong><em>آثار جانبية مهمة يجب الانتباه إليها: </em></strong></p><p dir="RTL">توقف عن تناول نابروكس واستشر الطبيب فورًا إذا حدثت لديك أي من الآثار الجانبية التالية، لأنك قد تحتاج إلى رعاية طبية عاجلة:</p><p dir="RTL"><strong>مشاكل خطيرة بالمعدة أو الأمعاء </strong></p><p dir="RTL">تتضمن العلامات:</p><ul dir="rtl"><li>نزيف من المعدة، يظهر ذلك على شكل قيء به دم، أو قطع تشبه ثفل القهوة.</li><li>نزيف من الشرج، يظهر ذلك على شكل براز لزج أسود أو إسهال به دم.</li><li>تكوَن قرحات أو ثقوب في معدتك أو أمعائك قد تكون أحيانا قاتلة خاصة عند كبار السن. تتضمن العلامات اضطراب في المعدة، ألم في المعدة، حمى، غثيان أو قيء.</li><li>مشاكل بالبنكرياس. تتضمن العلامات ألم شديد بالمعدة قد يمتد إلى الظهر.</li><li>ازدياد حالة التهاب القولون التقرحي أو مرض كرون سوءاً، يظهر ذلك على شكل ألم، إسهال، قيء وفقدان للوزن. &nbsp;</li></ul><p><strong>ردود الفعل التحسسية</strong></p><p dir="RTL">تتضمن العلامات:</p><ul dir="rtl"><li>تورم مفاجئ في الحلق، الوجه، اليدين أو القدمين.</li><li>صعوبة في التنفس أو ضيق بالصدر.</li><li>طفح جلدي أو نفطات أو حكة.</li></ul><p><strong>طفح جلدي شديد</strong></p><p dir="RTL">تتضمن العلامات:</p><ul dir="rtl"><li>طفح شديد يظهر بشكل سريع، يصاحبه نفطات أو تقشر في الجلد وقد تظهر النفطات أيضًا بالفم، الحلق أو العينين. وفي نفس الوقت قد تحدث حمى، صداع، سعال وآلام بالجسم.</li><li>ظهور نفطات على الجلد عند التعرض لضوء الشمس (البُرْفيرِيَّةٌ الجِلْدِيَّةُ الآجِلَةُ) وتلاحظ بشكل أكبر على الذراعين، الوجه واليدين.</li></ul><p><strong>مشاكل الكبد</strong></p><p dir="RTL">تتضمن العلامات:</p><ul dir="rtl"><li>اصفرار الجلد أو بياض العينين (اليرقان).</li><li>الشعور بالتعب، فقدان الشهية، الغثيان أو القيء ويصبح البراز شاحب اللون (التهاب الكبد) ومشاكل أخرى (تشمل التهاب الكبد)، تظهر في اختبارات الدم.</li></ul><p><strong>النوبة القلبية</strong></p><p dir="RTL">تتضمن العلامات:</p><ul dir="rtl"><li>ألم بالصدر قد يمتد إلى الرقبة والكتفين وإلى الأسفل باتجاه الذراع الأيسر.</li></ul><p dir="RTL"><strong>السكتة الدماغية</strong></p><p dir="RTL">تتضمن العلامات:</p><ul dir="rtl"><li>ضعف وتنميل بالعضلات. قد يصيب جانب واحد فقط من الجسم.</li><li>تغيّر مفاجئ في حاسة الشم، التذوق، السمع أو الإبصار، الارتباك.</li></ul><p dir="RTL"><strong>&nbsp;التهاب السحايا</strong></p><p dir="RTL">تتضمن العلامات:</p><ul dir="rtl"><li>حمى، غثيان أو قيء، تيبس الرقبة، صداع، حساسية للضوء الساطع وارتباك (على الأرجح لدى الأشخاص الذين يعانون من حالات تتعلق بالمناعة الذاتية مثل &rsquo;الذئبة الحماميَة المجموعيَة&lsquo;).</li></ul><p>توقف عن تناول نابروكس وأخبر طبيبك فورًا إذا لاحظت أي من الأعراض الجانبية الخطيرة السابقة.</p><p><strong><em>الآثار الجانبية المحتملة الأخرى: </em></strong></p><p dir="RTL"><strong>المعدة والأمعاء</strong></p><ul dir="rtl"><li>حرقة، عسر الهضم، التهاب بالمعدة (التهاب في الغشاء الداخلي للمعدة)، جفاف الفم، التهاب الحلق، انخفاض الشهية، ألم في المعدة، غثيان أو قيء، إمساك، إسهال، وريح، التهاب المرئ.</li></ul><p dir="RTL">من الممكن أن تكون الآثار الجانبية في المعدة قاتلة، خاصة عند كبار السن.</p><p><strong>الدم </strong></p><ul dir="rtl"><li>انخفاض عدد الصفيحات الدموية (قلة الصفيحات).</li><li>انخفاض تكدس الصفيحات.</li><li>ارتفاع أو انخفاض في خلايا الدم البيضاء.</li><li>انخفاض في كمية الصبغات الهيموغلوبينية الحاملة للأكسجين- في الدم (فقر الدم) و الذي يحدث بسبب انخفاض انتاج خلايا الدم الحمراء (عدم التنسج) أو ارتفاع تكسير خلايا الدم الحمراء (انحلال الدم).</li><li>ارتفاع مستوى البوتاسيوم في الدم (فرط بوتاسيوم الدم) أو التهاب في الأوعية الدموية (التهاب وعائي).</li></ul><p dir="RTL"><strong>الاضطرابات النفسية </strong></p><ul dir="rtl"><li>صعوبة في النوم أو تغيرات في أنماط أحلامك.</li><li>اكتئاب.</li><li>ارتباك أو رؤية وربما سماع أشياء لا وجود لها (الهلوسة).</li></ul><p><strong>الجهاز العصبي </strong></p><ul dir="rtl"><li>صداع.</li><li>نوبات أو تشنجات، شعور بالدوخة أو الدوار أو النعاس.</li><li>شعور كالوخز والإبر أو تنميل في يديك وقدميك.&nbsp;</li><li>صعوبة في التذكر أو التركيز.</li></ul><p><strong>العين والأذن </strong></p><ul dir="rtl"><li>تغيرات في الرؤية، ألم بالعين.</li><li>تغيرات في السمع، ويشمل ذلك سماع صوت رنين (طنين) في الأذن وفقدان السمع.</li><li>دوخة تسبب مشاكل في التوازن.</li></ul><p><strong>القلب والدورة الدموية </strong></p><ul dir="rtl"><li>تورم في اليدين، القدمين أو الساقين (الوذمة)، قد يصحب ذلك آلام في الصدر، إرهاق، ضيق في النفس (فشل القلب).</li><li>شعور برفرفة في القلب (خفقان)، بطء دقات القلب أو ارتفاع ضغط الدم.</li><li>مشاكل في طريقة ضخ القلب للدم حول الجسم أو تلف الأوعية الدموية. قد تتضمن العلامات الإرهاق، ضيق في النفس، الشعور بالإغماء وآلام عامة.</li></ul><p><strong>الصدر </strong></p><ul dir="rtl"><li>صعوبة في التنفس، تشمل ضيق في النفس، الأزيز أو السعال.</li><li>التهاب رئوي أو تورم بالرئة.</li></ul><p><strong>الجلد والشعر </strong></p><ul dir="rtl"><li>طفح جلدي يشمل الاحمرار، الشرى، البثور والنفطات على الجسم والوجه.</li><li>كدمات، حكة، تعرق، زيادة حساسية الجلد للشمس أو سقوط الشعر.</li></ul><p><strong>الجهاز البولي </strong></p><ul dir="rtl"><li>دم في البول أو مشاكل بالكلى.</li></ul><p dir="RTL"><strong>أخرى </strong></p><ul dir="rtl"><li>عطش، حمى، شعور بالإرهاق أو التوعك بشكل عام.</li><li>التهاب أو قرح بالفم.</li><li>ألم أو ضعف بالعضلات.</li><li>صعوبة في الحمل لدى السيدات.</li><li>&rsquo;الذئبة الحمامية المجموعية&lsquo;. تتضمن العلامات الحمى، الطفح الجلدي، مشاكل بالكلى وألم بالمفصل.</li></ul><p>يرجى الاتصال بالطبيب أو الصيدلي في حال أصبحت أي من الآثار الجانبية خطيرة أو في حال ظهور أية آثار جانبية جديدة لم تُذكر في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا يحفظ عند درجة حرارة أعلى من 30˚مئوية.</p><p dir="RTL">يحفظ داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية بعد &ldquo;EXP&rdquo;. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">لا تستخدم<strong> </strong>هذا الدواء إذا لاحظت أي علامات تلف واضحة عليه.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي نابروكسين الصوديوم.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من نابروكس 250 ملغم أقراص مغطاة بطبقة رقيقة على 275 ملغم نابروكسين الصوديوم يكافئ 250 ملغم نابروكسين.</p><p dir="RTL">يحتوي كل قرص مغطى بطبقة رقيقة من نابروكس دي.اس. 500 ملغم أقراص مغطاة بطبقة رقيقة على 550 ملغم نابروكسين الصوديوم يكافئ 500 ملغم نابروكسين.</p><p>المواد الأخرى المستخدمة في التركيبة التصنيعية هي: <em>لب القرص:</em> كبريتات لوريل الصوديوم، بوڤيدون، لاكتوز أحادي الماء، كروسكارميللوز الصوديوم، سيلليلوز بلوري مِكرويّ، زيت نباتي مهدرج، ثاني أكسيد السيليكون الغروي وستيرات المغنيسيوم. &nbsp;<em>غلاف القرص:</em> أوبادري أبيض.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right">نابروكس 250 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص بيضاء مغطاة بطبقة رقيقة، على شكل كبسولة، متوسطة الحجم ومنقوش عليها &quot;H1&quot; في أشرطة رقيقة من كلوريد متعدد الڤينيل/ثنائي كلوريد متعدد الڤينيليدين-الألومنيوم.</p><p dir="RTL" style="text-align:right">حجم العبوة: 20 قرص مغطى بطبقة رقيقة.</p><p style="text-align:right">نابروكس دي.اس. 500 ملغم أقراص مغطاة بطبقة رقيقة هي أقراص بيضاء مغطاة بطبقة رقيقة، على شكل كبسولة، منقوش عليها &quot;H2&quot; في أشرطة رقيقة من كلوريد متعدد الڤينيل/ثنائي كلوريد متعدد الڤينيليدين-الألومنيوم. &nbsp;</p><p dir="RTL" style="text-align:right">حجم العبوة: 10 أقراص مغطاة بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق</strong> <strong>والشركة المصنعة </strong></p><p>شركة أدوية الحكمة<br />بيادر وادي السير<br />المنطقة الصناعية<br />صندوق بريد 182400<br />عمان 11118، الأردن<br />هاتف: 5802900 (6-962) +<br />فاكس: 5817102 (6-962) +<br />الموقع الإلكتروني: www.hikma.com</p><p>&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">تحدث إلى الطبيب، الصيدلي، أو الممرض إذا عانيت من أية آثار جانبية. وذلك يشمل أي آثار جانبية لم يتم ذكرها في هذه النشرة. كما أنه يمكنك الإبلاغ عن هذه الآثار مباشرةً (انظر التفاصيل المذكورة أدناه). من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة بتوفير معلومات مهمة عن سلامة الدواء.</p><ul><li dir="RTL">&nbsp; &nbsp; المملكة العربية السعودية</li></ul><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.sa</p><ul><li dir="RTL">&nbsp; &nbsp; دول الخليج العربي الأخرى</li></ul><p dir="RTL">الرجاء الاتصال بالجهات الوطنية في كل دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة بتاريخ 03/2021، رقم النسخة SA2.0.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Naprox D.S. 500 mg Film- coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains 550 mg naproxen sodium equivalent to 500 mg naproxen.

Excipients with known effect: Lactose monohydrate and sodium. 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets. 

White capsule-shaped film-coated tablets engraved with “H2". 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Adults:</em></p><p>Treatment of rheumatoid arthritis, osteoarthritis (degenerative arthritis), ankylosing spondylitis, acute gout, acute musculoskeletal disorders and dysmenorrhoea.</p><p><em>Children:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p>Juvenile rheumatoid arthritis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4).</p><p><strong>Method of administration</strong></p><p>For oral administration.</p><p>To be taken preferably with or after food.</p><p><strong><em>&nbsp;</em></strong><strong><em>Adults</em></strong></p><p><em>Rheumatoid arthritis, osteoarthritis and ankylosing spondylitis</em></p><p>500 mg to 1 g taken in 2 doses at 12-hour intervals or alternatively, as a single administration.&nbsp; In the following cases a loading dose of 750 mg or 1 g per day for the acute phase is recommended:</p><p>a)&nbsp; In patients reporting severe night-time pain/or morning stiffness.</p><p>b) In patients being switched to naprox from a high dose of another antirheumatic compound.</p><p>c)&nbsp; In osteoarthrosis where pain is the predominant symptom.</p><p><strong><em>&nbsp;</em></strong><em>Acute gout</em></p><p>In acute gout an initial dose of 750 mg followed by 250mg every 8 hours until attack has passed; has been suggested.</p><p><em>&nbsp;Musculoskeletal disorders and dysmenorrhoea</em></p><p>500mg may be given initially followed by 250mg every 6 to 8 hours as required. Maximum daily dose after first day is 1250mg daily.</p><p><strong><em>&nbsp;</em></strong><strong><em>Older people</em></strong></p><p>Studies indicate that although total plasma concentration of naproxen is unchanged, the unbound plasma fraction of naproxen is increased in older people. The implication of this finding for naproxen dosing is unknown. As with other drugs used in older people it is prudent to use the lowest effective dose and for the shortest duration possible as older people patients are more prone to adverse events. The patient should be monitored regularly for GI bleeding during NSAID therapy. For the effect of reduced elimination in older people refer to Section 4.4.</p><p><strong><em>Pediatric population (over 5 years)</em></strong></p><p><em>For juvenile rheumatoid arthritis</em></p><p>A dose of 10mg per kg body weight daily in two divided doses at 12-hour intervals has been used in children over 5 years of age. Naprox are not recommended for use in any other indication in children under 16 years of age.</p><p><strong><em>Renal/hepatic impairment</em></strong></p><p>A lower dose should be considered in patients with renal or hepatic impairment. Naprox is contraindicated in patients with baseline creatinine clearance less than 30 ml/minute because accumulation of naproxen metabolites has been seen in patients with severe renal failure or those on dialysis (see section 4.3).</p><p>Treatment should be reviewed at regular intervals and discontinued if no benefit is seen or intolerance occurs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to any of the constituents.
•	Since the potential exists for cross-sensitivity reactions, naprox is contraindicated in patients who have previously shown hypersensitivity reactions (e.g. asthma, rhinitis, nasal polyps, angioedema or urticaria) in response to ibuprofen, aspirin, or other non-steroidal anti-inflammatory drugs. These reactions have the potential of being fatal. Severe anaphylactic-like reactions to naproxen have been reported in such patients.
•	Severe heart failure, hepatic failure and renal failure (See section 4.4 - Special warnings and precautions for use).
•	Third trimester of pregnancy (See section 4.6 - Pregnancy and lactation.
•	A history of gastrointestinal bleeding or perforation related to previous NSAIDs therapy. Active, or history of peptic ulcer/or active gastrointestinal bleeding (two or more distinct episodes of proven ulceration or bleeding).
•	In principle, naprox must not be administered to patients with gastrointestinal ulcerations, congestive gastritis or atrophic gastritis, gastrointestinal bleeding or other bleeding such as cerebrovascular bleeding.
•	Hemorrhoids or predisposition to rectal bleeding.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In all patients:</p><p>Undesirable effects may be minimized by using the minimum effective dose for the shortest possible duration necessary to control symptoms (see section 4.2 and GI and cardiovascular risks below).</p><p>Patients treated with NSAIDs long-term should undergo regular medical supervision to monitor for adverse events.</p><p>Older People:</p><p>Older people have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation, which may be fatal (See section 4.2- Posology and administration). Prolonged use of NSAIDs in these patients is not recommended. Where prolonged therapy is required patients should be reviewed regularly.</p><p>Severe gastrointestinal side effects may occur in patients who use prostaglandin synthetase inhibitors. The risk of developing gastrointestinal ulcers or bleeding increases with the duration of use and dose of naprox. This risk is not limited to a specific patient population, but older people and debilitated individuals exhibit poorer tolerance to gastrointestinal ulceration or bleeding than others. The majority of fatal gastrointestinal effects attributed to prostaglandin synthetase inhibitors occurred in this population.</p><p>The antipyretic and anti-inflammatory activities of naprox may reduce fever and inflammation, thereby diminishing their utility as diagnostic signs.</p><p><strong><em>Respiratory disorders:</em></strong></p><p>Caution is required if administered to patients suffering from, or with a previous history of, bronchial asthma since NSAIDs have been reported to precipitate bronchospasm in such patients.</p><p>Naproxen decreases platelet aggregation and prolongs bleeding time. This effect should be kept in mind when bleeding times are determined.</p><p><strong><em>Renal and Hepatic Impairment:</em></strong></p><p>Renal failure linked to reduced prostaglandin production.</p><p>The administration of an NSAID may cause a dose dependent reduction in prostaglandin formation and precipitate renal failure. Patients at greatest risk of this reaction are those with impaired renal function, cardiac impairment, liver dysfunction, especially in the case of long-term treatment, those taking diuretics and older people Care must also be taken to ensure adequate diuresis. In the event of reduced renal perfusion, it is recommended to monitor renal function before and during treatment with naprox (See also section 4.3-Contraindications).</p><p><strong><em>&nbsp;</em></strong><strong><em>Use in patients with impaired renal function</em></strong></p><p>As naproxen is eliminated to a large extent (95%) by urinary excretion via glomerular filtration, it should be used with great caution in patients with impaired renal function and the monitoring of serum creatinine and/or creatinine clearance is advised in these patients. Naprox is contraindicated in patients having a baseline creatinine clearance of less than 30ml/minute.</p><p>Haemodialysis does not decrease the plasma concentration of naproxen because of the high degree of protein binding.</p><p>Certain patients, specifically those whose renal blood flow is compromised, such as in extracellular volume depletion, cirrhosis of the liver, sodium restriction, congestive heart failure, and pre-existing renal disease, should have renal function assessed before and during naprox therapy. Some older people in whom patient impaired renal function may be expected, as well as patients using diuretics, may also fall within this category. A reduction in daily dosage should be considered to avoid the possibility of excessive accumulation of naproxen metabolites in these patients.</p><p><strong><em>Use in patients with impaired liver function</em></strong></p><p>Care should also be exercised in patients with hepatic insufficiency.</p><p>Caution is advised when high doses of naproxen are administered to older people patients, because there are indications that the quantity of non-protein-bound naproxen increases in such patients. Since naproxen has an anti-inflammatory, analgesic and antipyretic effect, certain symptoms of infection can therefore be masked.</p><p>Chronic alcoholic liver disease and probably also other forms of cirrhosis reduce the total plasma concentration of naproxen, but the plasma concentration of unbound naproxen is increased. The implication of this finding for naproxen dosing is unknown but it is prudent to use the lowest effective dose.</p><p>As with other non-steroidal anti-inflammatory drugs, elevations of one or more liver function tests may occur. Hepatic abnormalities may be the result of hypersensitivity rather than direct toxicity. Severe hepatic reactions, including jaundice and hepatitis (some cases of hepatitis have been fatal) have been reported with this drug as with other non-steroidal anti-inflammatory drugs. Cross reactivity has been reported.</p><p><strong><em>Gastrointestinal bleeding, ulceration and perforation</em></strong></p><p><strong><em>&nbsp;</em></strong>GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without warning symptoms or a previous history of serious GI events.</p><p>The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), when used with alcohol, in smoking and in older people. These patients should commence treatment on the lowest dose available.</p><p>Patients with a history of GI toxicity, particularly when older people, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.</p><p>Caution should be advised in patients receiving concomitant medications which could increase the risk of gastrotoxicity or bleeding, such as corticosteroids, or anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents such as aspirin (see section 4.5- Interactions). If a corticosteroid is replaced by naproxen and the substitution occurs partially or fully, the usual precautions which come into consideration when discontinuing corticosteroid treatment should be applied.</p><p>When GI bleeding or ulceration occurs in patients receiving naprox, the treatment should be withdrawn.</p><p>NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn&#39;s disease) as these conditions may be exacerbated (see section 4.8 - Undesirable effects).</p><p>Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see section 4.5).</p><p><strong><em>&nbsp;</em></strong><strong><em>Haematological</em></strong></p><p>Patients who have coagulation disorders or are receiving drug therapy that interferes with haemostasis should be carefully observed if naproxen-containing products are administered.</p><p>Patients at high risk of bleeding or who use coumarin derivatives or heparin alongside naproxen have an increased risk of bleeding. The benefits in that case should be weighed up against the risks. In any case concomitant use of naproxen with a high dose of heparin (or derivatives thereof) is not recommended.</p><p><strong><em>Anaphylactic (anaphylactoid) reactions</em></strong></p><p>Hypersensitivity reactions may occur in susceptible individuals. Anaphylactic (anaphylactoid) reactions may occur both in patients with and without a history of hypersensitivity or exposure to aspirin, other non-steroidal anti-inflammatory drugs or naproxen-containing products. They may also occur in individuals with a history of angio-oedema, bronchospastic reactivity (e.g. asthma), rhinitis and nasal polyps.</p><p>Anaphylactoid reactions, like anaphylaxis, may have a fatal outcome.</p><p><strong><em>&nbsp;</em></strong><strong><em>Steroids</em></strong></p><p>If steroid dosage is reduced or eliminated during therapy, the steroid dosage should be reduced slowly and the patients must be observed closely for any evidence of adverse effects, including adrenal insufficiency and exacerbation of symptoms of arthritis.</p><p><strong><em>Ocular effects</em></strong></p><p>Studies have not shown changes in the eye attributable to naproxen administration. In rare cases, adverse ocular disorders including papillitis, retrobulbar optic neuritis and papilloedema, have been reported in users of NSAIDs including naproxen, although a cause-and-effect relationship cannot be established; accordingly, patients who develop visual disturbances during treatment with naproxen-containing products should have an ophthalmological examination.</p><p><strong><em>Cardiovascular and cerebrovascular effects</em></strong></p><p>Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy.</p><p>Mild peripheral oedema has been observed in a few patients receiving naproxen. Although sodium retention has not been reported in metabolic studies, it is possible that patients with questionable or compromised cardiac function may be at a greater risk when taking naproxen.</p><p>Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Although data suggest that the use of naproxen (1000mg daily) may be associated with a lower risk, some risk cannot be excluded.</p><p>Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with naprox after careful consideration. Similar consideration should be made before initiating longer-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking).</p><p><strong><em>Dermatological</em></strong></p><p><strong><em>&nbsp;</em></strong>Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens- Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see 4.8). Patients appear to be at highest risk for these reactions early in the course of therapy: the onset of the reactions occurring in the majority of cases within the first month of treatment. Naproxen should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity. If the skin becomes delicate or in the event of blistering or other symptoms of pseudoporphyria, treatment should be discontinued and the patient should be carefully monitored.</p><p><strong><em>Combination with other NSAIDs</em></strong></p><p>The combination of naproxen-containing products and other NSAIDs, including cyclooxygenase-2 selective inhibitors, is not recommended, because of the cumulative risks of inducing serious NSAID-related adverse events.</p><p><strong><em>SLE and mixed connective tissue disease</em></strong></p><p>In patients with systemic lupus erythrematosus (SLE) and mixed connective tissue disorders there may be an increased risk of aseptic meningitis (see section 4.8 - Undesirable effects).</p><p><strong><em>Interference in tests:</em></strong></p><p>It is suggested that naproxen therapy be temporarily discontinued 48 hours before adrenal function tests are performed, because naproxen may artifactually interfere with some tests for 17-ketogenic steroids. Similarly, naproxen may interfere with some assays of urinary 5-hydroxyindoleacetic acid.</p><p>Sporadic abnormalities in laboratory tests (e.g. liver function test) have occurred in patients on naproxen therapy, but no definite trend was seen in any test indicating toxicity.</p><p><strong>Naprox contains lactose monohydrate</strong></p><p>Naprox contains lactose monohydrate. Each film-coated tablet contains 200 mg lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>Naprox contains sodium. Each film-coated tablet contains 56.882 mg sodium (main component of cooking/table salt). This is equivalent to 2.84% of the recommended maximum daily dietary intake of sodium for an adult. Patients on a sodium controlled diet should take this into consideration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Antacid or colestyramine</em></strong></p><p>&nbsp;Concomitant administration of antacid or colestyramine can delay the absorption of naproxen but does not affect its extent. Naprox should be taken at least one hour before or four to six hours after colestyramine.</p><p><strong><em>Food</em></strong></p><p>&nbsp;Concomitant administration of food can delay the absorption of naproxen, but does not affect its extent.</p><p><strong><em>Other analgesics including cyclooxygenase-2 selective inhibitors</em></strong></p><p>&nbsp;Avoid concomitant use of two or more NSAIDs (including aspirin) as this may increase the risk of adverse effects (see section 4.4).</p><p><strong><em>Anti-hypertensives</em></strong></p><p>&nbsp;Reduced anti-hypertensive effect. Concomitant administration of naprox with beta blockers may reduce their antihypertensive effect and may increase the risk of renal impairment associated with the use of ACE inhibitors or angiotensin II receptor antagonists.</p><p><strong><em>Diuretics</em></strong></p><p>Caution is advised when naproxen is co-administered with diuretics as there can be a decreased diuretic effect. The natriuretic effect of furosemide has been reported to be inhibited by some drugs of this class. Diuretics can increase the risk of nephrotoxicity of NSAIDs.</p><p><strong><em>Cardiac glycosides</em></strong></p><p>&nbsp;NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels.</p><p><strong><em>Lithium</em></strong></p><p>Inhibition of renal lithium clearance leading to increases in plasma lithium concentrations has also been reported following administration of these agents.</p><p><strong><em>Methotrexate</em></strong></p><p>Caution is advised where methotrexate is given concurrently because of possible enhancement of its toxicity, since naproxen, among other non-steroidal anti-inflammatory drugs, has been reported to reduce the tubular secretion of methotrexate in an animal model.</p><p><strong><em>Ciclosporin</em></strong></p><p>&nbsp;Increased risk of nephrotoxocity.</p><p><strong><em>Mifepristone</em></strong></p><p>NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.</p><p><strong><em>Corticosteroids</em></strong></p><p>&nbsp;As with all NSAIDs, caution should be taken when co-administering with cortico-steroids because of the increased risk of gastrointestinal ulceration or bleeding.</p><p><strong><em>Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs)</em></strong></p><p>Increased risk of GI bleeding (see section 4.4 &ndash; Special warning and precautions for use) when anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs) are combined with NSAIDs.</p><p><strong><em>Anti-coagulants</em></strong></p><p>It is considered unsafe to take NSAIDs in combination with anti-coagulants such as warfarin or heparin unless under direct medical supervision, as NSAIDs may enhance the effects of anti-coagulants (see Section 4.4).</p><p><strong><em>Effect of high plasma protein binding of naproxen on other drugs</em></strong></p><p>Due to the high plasma protein binding of naproxen, patients simultaneously receiving hydantoins, anticoagulants, other NSAIDs, aspirin or a highly protein-bound sulphonamide should be observed for signs of overdosage of these drugs. Patients simultaneously receiving naprox and a hydantoin, sulphonamide or sulfonylurea should be observed for adjustment of dose if required. No interactions have been observed in clinical studies with naproxen and anticoagulants or sulfonylureas, but caution is nevertheless advised since interaction has been seen with other non-steroidal agents of this class.</p><p><strong><em>Probenecid</em></strong></p><p>Probenecid given concurrently increases naproxen plasma levels and extends its half-life considerably.</p><p><strong><em>Zidovudine</em></strong></p><p>There is an increased risk of haematological toxicity when NSAIDs are given with zidovudine. There is evidence of an increased risk of haemarthroses and haematoma in HIV(+) haemophiliacs receiving concurrent treatment with zidovudine and ibuprofen.</p><p><strong><em>Bisphosphonates</em></strong>: concomitant use of bisphosphonates and NSAIDs may increase the risk of gastric mucosal damage.</p><p><strong><em>Quinolone antibiotics</em></strong></p><p>Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.</p><p><strong><em>Tacrolimus</em></strong></p><p>Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus.</p><p><strong><em>Acetylsalicylic acid</em></strong></p><p>Clinical pharmacodynamic data suggest that concomitant naproxen usage for more than one day consecutively may inhibit the effect of low-dose acetylsalicylic acid on platelet activity and this inhibition may persist for up to several days after stopping naproxen therapy. The clinical relevance of this interaction is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy</em></strong></p><p>Congenital abnormalities have been reported in association with NSAID administration in man; however, these are low in frequency and do not appear to follow any discernible pattern. As with other drugs of this type, naproxen produces delay in parturition in animals and also affects the human foetal cardiovascular system (closure of ductus arteriosus). Use of naprox in the last trimester of pregnancy is contraindicated (see Section 4.3). NSAIDs should not be used during the first two trimesters of pregnancy, unless the potential benefit to the patient outweighs the potential risk to the foetus.</p><p><strong><em>Labour and delivery</em></strong></p><p>Naproxen containing products are not recommended in labour and delivery because, through its prostaglandin synthesis inhibitory effect, naproxen may adversely affect foetal circulation and inhibit contractions, with an increased bleeding tendency in both mother and child.</p><p><strong><em>Breast feeding</em></strong></p><p>Naproxen has been found in the milk of lactating women. The use of naprox should be avoided in patients who are breast-feeding.</p><p><strong><em>&nbsp;</em></strong><strong><em>Fertility</em></strong></p><p>The use of naprox, as with any drug known to inhibit cyclooxygenase/prostaglandin synthesis, may impair fertility and is not recommended in women attempting to conceive. In women who have difficulty conceiving or are undergoing investigation of infertility, withdrawal of naprox should be considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects such as dizziness, vertigo, insomnia, drowsiness, fatigue and visual disturbances or depression are possible after taking naprox. If patient experiences these or similar undesirable effects, they should not drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following adverse events have been reported with NSAIDs and with naprox.</p><p><em>Gastrointestinal disorders:</em></p><p>The most commonly observed adverse events are gastrointestinal in nature. Heartburn, nausea, vomiting, constipation, diarrhoea, flatulence, dyspepsia, abdominal discomfort and epigastric distress. More serious reactions which may occur are gastro-intestinal bleeding, which is sometimes fatal, particularly in older people (see section 4.4), inflammation, ulceration, perforation, and obstruction of the upper and lower gastrointestinal tract, melaena, haematemesis, stomatitis, exacerbation of ulcerative colitis and Crohn&rsquo;s disease (see section 4.4), oesophagitis, gastritis and pancreatitis.</p><p><em>Blood and lymphatic system disorders: </em></p><p>Neutropenia, thrombocytopenia, granulocytopenia including agranulocytosis, eosinophilia, leucopenia, aplastic anaemia and haemolytic anaemia.</p><p><em>Immune system disorders</em>:</p><p>Hypersensitivity reactions have been reported following treatment with NSAIDs in patients with, or without, a history of previous hypersensitivity reactions to NSAIDs. These may consist of (a) nonspecific allergic reactions and anaphylaxis (b) respiratory tract reactivity comprising asthma, aggravated asthma, bronchospasm or dyspnoea, or (c) assorted skin disorders, including rashes of various types, pruritus, urticaria, purpura, angio-oedema and more rarely exfoliative and bullous dermatoses (including epidermal necrolysis and erythema multiforme).</p><p><em>&nbsp;Metabolic and nutrition disorders</em>:</p><p>Hyperkalaemia.</p><p><em>&nbsp;Psychiatric disorders</em>:</p><p>Insomnia, dream abnormalities, depression, confusion and hallucinations.</p><p><em>Cardiac disorders</em></p><p>Oedema, palpitations, cardiac failure and congestive heart failure have been reported in association with NSAID treatment.</p><p>Clinical trial and epidemiological data suggest that use of coxibs and some NSAIDs (particularly at high doses and in long term treatment) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).</p><p>Vascular disorders</p><p>Hypertension, vasculitis.</p><p>Hepatobiliary disorders</p><p>abnormal liver function, hepatitis (including some fatalities) and jaundice.</p><p><em>Nervous system disorders:</em></p><p>convulsions, dizziness, headache, lightheadedness, drowsiness, inability to concentrate and cognitive dysfunction, retrobulbar optic neuritis, paraesthesia, exacerbation of parkinson&#39;s disease, reports of aseptic meningitis (especially in patients with existing auto-immune disorders, such as systemic lupus erythematosus, mixed connective tissue disease), with symptoms such as stiff neck, headache, nausea, vomiting, fever and disorientation (see section 4.4), nervousness, euphoria, low temperature and drowsiness.</p><p><em>&nbsp;Haematological</em></p><p>Thrombocytopenia, eosinophilia, leucopenia, neutropenia, agranulocytosis, decreased platelet aggregation, prolonged bleeding time, aplastic anaemia and haemolytic anaemia. decrease in hemoglobin levels and/or hematocrit, granulocytopenia.</p><p><em>Eye Disorders</em></p><p>Corneal opacity, blurred vision, visual disturbances, papillitis and papilloedema.</p><p><em>Ear and Labyrinth disorders</em></p><p>hearing disturbances including impairment, tinnitus, and vertigo.</p><p><em>&nbsp;Respiratory, thoracic and mediastinal disorders</em></p><p>Dyspnoea, asthma, eosinophilic pneumonitis and pulmonary oedema.</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Skin rashes including fixed drug eruption, itching (pruritus), urticaria, ecchymoses, purpura, sweating. Alopecia, erythema multiforme, skin eruption, Stevens Johnson syndrome, erythema nodosum, lichen planus, pustular reaction, SLE, epidermal necrolysis, very rarely toxic epidermal necrolysis, photosensitivity reactions (including cases in which skin resembles porphyria cutanea tarda &ldquo;pseudoporphyria&rdquo;) or epidermolysis bullosa-like reactions which may occur rarely.</p><p>If skin fragility, blistering or other symptoms suggestive of pseudoporphyria occur, treatment should be discontinued and the patient monitored.</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p>Myalgia and muscle weakness.</p><p><em>Renal and urinary disorders</em></p><p>Including, but not limited to, glomerular nephritis, interstitial nephritis, nephrotic syndrome, haematuria, raised serum creatinine, renal papillary necrosis and renal failure.</p><p><em>Reproductive system and breast disorders</em></p><p>Female infertility.</p><p><em>General disorders and administration site conditions</em></p><p>Thirst, pyrexia, fatigue and malaise.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999<br />e-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><ul><li>Other GCC States</li></ul><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Symptoms include headache , nausea , vomiting, epigastric pain, gastrointestinal bleeding, rarely diarrhoea, disorientation, excitation, coma, heartburn, drowsiness, dizziness, tinnitus, fainting, occasionally convulsions, transient changes in liver function, hypothrombinemia, apnea and metabolic acidosis. In cases of significant poisoning acute renal failure and liver damage are possible.</p><p><u>Management</u></p><p>Patients should be treated symptomatically as required. Within one hour of ingestion of a potentially toxic amount activated charcoal should be considered. Alternatively in adults gastric lavage should be considered within one hour of ingestion of a potentially life-threatening overdose.</p><p>Good urine output should be ensured.</p><p>Renal and liver function should be closely monitored.</p><p>Patients should be observed for at least four hours after ingestion of potentially toxic amounts.</p><p>Frequent or prolonged convulsions should be treated with intravenous diazepam.</p><p>Other measures may be indicated by the patient&rsquo;s clinical condition.</p><p>Haemodialysis does not decrease the plasma concentration of naproxen because of the high degree of protein binding. However, haemodialysis may still be appropriate in a patient with renal failure who has taken naproxen.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids. ATC code: M01AE02.</p><p>Naproxen is a non-steroidal anti-inflammatory analgesic compound with antipyretic properties as has been demonstrated in classical animal test systems. Naproxen exhibits its anti-inflammatory effect even in adrenalectomised animals, indicating that its action is not mediated through the pituitary-adrenal axis.</p><p>Naproxen inhibits prostaglandin synthetase (as do other NSAIDs). As with other NSAIDs, however, the exact mechanism of its anti-inflammatory action is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Naproxen is completely absorbed from the gastro-intestinal tract, and peak plasma levels are reached in 2 to 4 hours. Naproxen is present in the blood mainly as unchanged drug, extensively bound to plasma proteins. The plasma half-life is between 12 and 15 hours, enabling a steady state to be achieved within 3 days of initiation of therapy on a twice daily dose regimen. The degree of absorption is not significantly affected by either foods or most antacids. Excretion is almost entirely via the urine, mainly as conjugated naproxen, with some unchanged drug. Metabolism in children is similar to that in adults. Chronic alcoholic liver disease reduces the total plasma concentration of naproxen but the concentration of unbound naproxen increases. In older people, the unbound plasma concentration of naproxen is increased although total plasma concentration is unchanged.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.</p><p><strong>&nbsp;</strong><em>Carcinogenicity</em></p><p>Naproxen was administered with food to Sprague-Dawley rats for 24 months at doses of 8, 16 and 24mg/kg/day. Naproxen was not carcinogenic in rats.</p><p><em>&nbsp;Mutagenicity </em></p><p>Mutagenicity was not seen in <em>salmonella typhimurium</em> (5 cell lines), <em>Sachharomyces cerevisisae</em> (1 cell line) and mouse lymphoma tests.</p><p><em>Fertility </em></p><p>Naproxen did not affect the fertility of rats when administered orally at doses of 30mg/kg/day to males and 20mg/kg/day to females.</p><p><em>Teratogenicity </em></p><p>Naproxen was not teratogenic when administered orally at doses of 20mg/kg/day during organogenesis to rats and rabbits.</p><p><em>Perinatal/Postnatal Reproduction </em></p><p>Oral administration of naproxen to pregnant rats at doses of 2, 10 and 20mg/kg/day during the third trimester of pregnancy resulted in difficult labour.&nbsp; These are known effects of this class of compounds and were demonstrated in pregnant rats with aspirin and indometacin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Tablet core:</em></p><p>-&nbsp;&nbsp; Sodium lauryl sulfate</p><p>-&nbsp;&nbsp; Povidone</p><p>-&nbsp;&nbsp; Lactose monohydrate</p><p>-&nbsp;&nbsp; Croscarmellose sodium</p><p>-&nbsp;&nbsp; Microcrystalline cellulose</p><p>-&nbsp;&nbsp; Hydrogenated vegetable oil</p><p>-&nbsp;&nbsp; Colloidal silicon dioxide</p><p>-&nbsp;&nbsp; Magnesium stearate</p><p><em>Tablet coat: </em></p><p>-&nbsp;&nbsp; Opadry white&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/PVDC-aluminum foil blisters.</p><p>Pack size: 10 Film-coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hikma Pharmaceuticals 
Bayader Wadi El Seer 
Industrial Area 
P.O. Box 182400 
Amman 11118, Jordan
Tel: + (962-6) 5802900
Fax: + (962-6) 5817102
Website: www.hikma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                17 March 2021 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>